PDCD1 and diffuse large B-cell lymphoma: The study suggests that PD-1 blockade therapy may be effective for patients with relapsed or refractory DLBCL who did not respond adequately to CAR-T cell therapy and who exhibit high levels of PD-1 in T-cells infiltrated by tumors (126).